Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
4.000
-0.230 (-5.44%)
Jun 8, 2026, 4:00 PM EDT - Market closed
Iovance Biotherapeutics Employees
Iovance Biotherapeutics had 975 employees as of December 31, 2025. The number of employees increased by 137 or 16.35% compared to the previous year.
Employees
975
Change (1Y)
137
Growth (1Y)
16.35%
Revenue / Employee
$292,931
Profits / Employee
-$362,933
Market Cap
1.79B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 975 | 137 | 16.35% |
| Dec 31, 2024 | 838 | 281 | 50.45% |
| Dec 31, 2023 | 557 | 54 | 10.74% |
| Dec 31, 2022 | 503 | 184 | 57.68% |
| Dec 31, 2021 | 319 | 78 | 32.37% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Recursion Pharmaceuticals | 600 |
| Lakefront Biotherapeutics NV | 558 |
| Vericel | 398 |
| Ocular Therapeutix | 325 |
| Viridian Therapeutics | 252 |
| Zymeworks | 243 |
| Stoke Therapeutics | 170 |
IOVA News
- 4 days ago - Iovance Biotherapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 5 days ago - Iovance receives Australian approval of Amtagvi for advanced melanoma - TheFly
- 5 days ago - Iovance's Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia - GlobeNewsWire
- 7 days ago - Iovance gets allowance to proceed from FDA for IOV-5001 IND application - TheFly
- 7 days ago - Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001 - GlobeNewsWire
- 17 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 18 days ago - Iovance Biotherapeutics to Present at Upcoming Conference - GlobeNewsWire
- 4 weeks ago - Iovance Biotherapeutics price target lowered to $14 from $16 at Chardan - TheFly